Bristol Myers: acquisition of RayzeBio finalized
The pharmaceutical company recalls that it had successfully completed its tender offer for RayzeBio at the end of last week, with approximately 53 million shares having been validly tendered, representing around 86% of RayzeBio's common shares.
"This transaction provides us with radiopharmaceutical therapeutics (RPT), one of the fastest-growing new treatment modalities for patients with solid tumors", emphasizes CEO Chris Boerner.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction